JPH11509194A - 睡眠障害治療用の非アロステリックgaba▲下a▼アゴニスト - Google Patents
睡眠障害治療用の非アロステリックgaba▲下a▼アゴニストInfo
- Publication number
- JPH11509194A JPH11509194A JP9504631A JP50463197A JPH11509194A JP H11509194 A JPH11509194 A JP H11509194A JP 9504631 A JP9504631 A JP 9504631A JP 50463197 A JP50463197 A JP 50463197A JP H11509194 A JPH11509194 A JP H11509194A
- Authority
- JP
- Japan
- Prior art keywords
- gaba
- agonist
- pharmaceutical composition
- sleep
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.非アロステリックGABAAアゴニストを含む睡眠障害治療用の医薬組成物。 2.非アロステリックGABAAアゴニストがGABAA受容体に直接効果を及ぼすもので ある、請求項1記載の医薬組成物。 3.GABAAアゴニストが部分的アゴニストである、請求項2記載の医薬組成物。 4.GABAAアゴニストが間接的GABAアゴニストである、請求項1記載の医薬組成 物。 5.非アロステリックGABAAアゴニストがGABA取り込み阻害剤である、請求項4 記載の医薬組成物。 6.非アロステリックGABAAアゴニストがGABAトランスアミナーゼ阻害剤である 、請求項4記載の医薬組成物。 7.非アロステリックGABAAアゴニストがGABAプロドラッグである、請求項4記 載の医薬組成物。 8.非アロステリックGABAAアゴニストがムシモール、チオムシモール、THIP、 チオTHIPまたはイソグバシンである、請求項4記載の医薬組成物。 9.非アロステリックGABAAアゴニストがプロガビドである、請求項7記載の医 薬組成物。 10.非アロステリックGABAAアゴニストがチアガビンである、請求項5記載の医 薬組成物。 11.患者が年輩者である、請求項1記載の医薬組成物。 12.睡眠障害が入眠困難である、請求項1記載の医薬組成物。 13.睡眠障害が夜間の頻繁な覚醒である、請求項1記載の医薬組成物。 14.投与するアゴニストの量が、1日あたり5〜50mgである、請求項1記載の医 薬組成物。 15.非アロステリックGABAAアゴニストの、請求項1-14のいずれか1項に定義さ れた医薬組成物の製造への使用。 16.患者に催眠効果を有する量の非アロステリックGABAAアゴニストを投与する ことを含む、治療を必要とする患者の睡眠障害を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19525598.4 | 1995-07-13 | ||
DE19525598A DE19525598C2 (de) | 1995-07-13 | 1995-07-13 | Schlafmittel |
PCT/EP1996/003018 WO1997002813A1 (en) | 1995-07-13 | 1996-07-10 | Non-allosteric gabaa agonists for treating sleep disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004256133A Division JP2005047925A (ja) | 1995-07-13 | 2004-09-02 | 睡眠障害治療用の非アロステリックgabaaアゴニスト |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11509194A true JPH11509194A (ja) | 1999-08-17 |
JP3754705B2 JP3754705B2 (ja) | 2006-03-15 |
Family
ID=7766768
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50463197A Expired - Fee Related JP3754705B2 (ja) | 1995-07-13 | 1996-07-10 | 睡眠障害治療用の非アロステリックgaba▲下a▼アゴニスト |
JP2004256133A Pending JP2005047925A (ja) | 1995-07-13 | 2004-09-02 | 睡眠障害治療用の非アロステリックgabaaアゴニスト |
JP2008215117A Pending JP2009057382A (ja) | 1995-07-13 | 2008-08-25 | 睡眠障害治療用の非アロステリックgabaaアゴニスト |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004256133A Pending JP2005047925A (ja) | 1995-07-13 | 2004-09-02 | 睡眠障害治療用の非アロステリックgabaaアゴニスト |
JP2008215117A Pending JP2009057382A (ja) | 1995-07-13 | 2008-08-25 | 睡眠障害治療用の非アロステリックgabaaアゴニスト |
Country Status (12)
Country | Link |
---|---|
US (1) | US5929065A (ja) |
EP (3) | EP0867184B1 (ja) |
JP (3) | JP3754705B2 (ja) |
AT (3) | ATE207349T1 (ja) |
AU (1) | AU723954B2 (ja) |
CA (1) | CA2226582C (ja) |
CL (1) | CL2003002785A1 (ja) |
DE (4) | DE19525598C2 (ja) |
DK (3) | DK0867178T3 (ja) |
ES (3) | ES2166110T3 (ja) |
PT (3) | PT867178E (ja) |
WO (1) | WO1997002813A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914333A (en) * | 1996-07-31 | 1999-06-22 | Novo Nordisk A/S | Treatment of psychotic disorders |
DE69803670T2 (de) * | 1997-08-01 | 2002-11-21 | Elan Corp. Plc, Dublin | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung |
IE970588A1 (en) | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
JP2003510266A (ja) * | 1999-09-28 | 2003-03-18 | ハー・ルンドベック・アクチエゼルスカベット | 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形 |
DK1296671T3 (da) * | 2000-06-26 | 2008-06-16 | Warner Lambert Co | Gabapentinanaloger til sövnforstyrrelser |
WO2002094225A1 (en) * | 2001-05-21 | 2002-11-28 | H. Lundbeck A/S | Granular preparations of gaboxadol |
PT1641456E (pt) | 2003-06-25 | 2010-06-01 | Lundbeck & Co As H | Gaboxadol para o tratamento de depressão e outros distúrbios afectivos |
AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
US20070032553A1 (en) * | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
WO2005060968A1 (en) * | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
TW200528098A (en) * | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
EP1696959A2 (en) * | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
ATE454140T1 (de) * | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
US20080269278A1 (en) * | 2004-04-02 | 2008-10-30 | H. Lundbeck A/S | Treatment of Impaired Respiratory Function with Gaboxadol |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
JP5380930B2 (ja) * | 2007-07-24 | 2014-01-08 | 大正製薬株式会社 | 睡眠改善剤 |
EP3372229B1 (en) | 2014-06-06 | 2021-03-24 | Ovid Therapeutics, Inc. | Methods of increasing tonic inhibition and treating angelman syndrome |
PT3274331T (pt) | 2015-03-24 | 2020-04-02 | H Lundbeck As | Fabrico de 4,5,6,7-tetra-hidroisoxazolo[5,4-c]- piridin-3-ol |
US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
CA2992734A1 (en) | 2015-07-17 | 2017-01-26 | Ovid Therapeutics, Inc. | Methods of treating developmental disorders with gaboxadol |
JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. | てんかん性障害の処置のための方法および組成物 |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
KR20210062662A (ko) | 2018-09-20 | 2021-05-31 | 오비드 테라퓨틱스 인크. | 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용 |
GB2594616A (en) | 2018-11-21 | 2021-11-03 | Certego Therapeutics Inc | Gaboxadol for reducing risk of suicide and rapid relief of depression |
US11986714B2 (en) | 2018-12-14 | 2024-05-21 | Raimondo Fazio | Martial arts training device |
AU2019405489A1 (en) | 2018-12-17 | 2021-06-10 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
KR20220114572A (ko) | 2019-12-18 | 2022-08-17 | 오비드 테라퓨틱스 인크. | 1p36 결실 증후군의 치료적 치료를 위한 가복사돌 |
TW202208373A (zh) | 2020-05-20 | 2022-03-01 | 美商瑟泰戈治療學股份有限公司 | 環經氘化之加波沙朵及其用於治療精神病症用途 |
CA3228780A1 (en) * | 2021-08-11 | 2023-02-16 | Brian TANCOWNY | Amanita muscaria extracts and compounds and their beneficial and therapeutic use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362731A (en) * | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4786647A (en) * | 1986-06-30 | 1988-11-22 | University Of Florida | Method for eliciting anxiolysis |
US5167228A (en) * | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5185446A (en) * | 1990-09-04 | 1993-02-09 | Neurogen Corporation | Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands |
DK58291D0 (da) * | 1991-04-02 | 1991-04-02 | Novo Nordisk As | Krystalinsk stof og dets fremstilling |
US6077839A (en) * | 1992-03-19 | 2000-06-20 | Allergan Sales, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists |
-
1995
- 1995-07-13 DE DE19525598A patent/DE19525598C2/de not_active Expired - Fee Related
-
1996
- 1996-03-01 US US08/609,461 patent/US5929065A/en not_active Expired - Lifetime
- 1996-07-10 DK DK98102355T patent/DK0867178T3/da active
- 1996-07-10 ES ES98102355T patent/ES2166110T3/es not_active Expired - Lifetime
- 1996-07-10 JP JP50463197A patent/JP3754705B2/ja not_active Expired - Fee Related
- 1996-07-10 ES ES98102356T patent/ES2166111T3/es not_active Expired - Lifetime
- 1996-07-10 AT AT96925704T patent/ATE207349T1/de not_active IP Right Cessation
- 1996-07-10 DK DK98102356T patent/DK0867184T3/da active
- 1996-07-10 PT PT98102355T patent/PT867178E/pt unknown
- 1996-07-10 EP EP98102356A patent/EP0867184B1/en not_active Expired - Lifetime
- 1996-07-10 DE DE69616333T patent/DE69616333T2/de not_active Expired - Fee Related
- 1996-07-10 AT AT98102356T patent/ATE207356T1/de not_active IP Right Cessation
- 1996-07-10 DE DE69616375T patent/DE69616375T2/de not_active Expired - Fee Related
- 1996-07-10 ES ES96925704T patent/ES2165990T3/es not_active Expired - Lifetime
- 1996-07-10 EP EP96925704A patent/EP0840601B1/en not_active Expired - Lifetime
- 1996-07-10 PT PT96925704T patent/PT840601E/pt unknown
- 1996-07-10 DK DK96925704T patent/DK0840601T3/da active
- 1996-07-10 CA CA002226582A patent/CA2226582C/en not_active Expired - Fee Related
- 1996-07-10 AT AT98102355T patent/ATE207352T1/de not_active IP Right Cessation
- 1996-07-10 DE DE69616376T patent/DE69616376T2/de not_active Expired - Fee Related
- 1996-07-10 PT PT98102356T patent/PT867184E/pt unknown
- 1996-07-10 WO PCT/EP1996/003018 patent/WO1997002813A1/en active IP Right Grant
- 1996-07-10 EP EP98102355A patent/EP0867178B1/en not_active Expired - Lifetime
- 1996-07-10 AU AU66137/96A patent/AU723954B2/en not_active Ceased
-
2003
- 2003-12-30 CL CL200302785A patent/CL2003002785A1/es unknown
-
2004
- 2004-09-02 JP JP2004256133A patent/JP2005047925A/ja active Pending
-
2008
- 2008-08-25 JP JP2008215117A patent/JP2009057382A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3754705B2 (ja) | 睡眠障害治療用の非アロステリックgaba▲下a▼アゴニスト | |
AU2021273588B2 (en) | Melatonin agonist treatment | |
AU747751B2 (en) | Use of cabergoline in the treatment of restless legs syndrome | |
Skocbat et al. | Melatonin-the key to the gate of sleep | |
JPH06508836A (ja) | 光学的に純粋なr(+)オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 | |
JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
Frattola et al. | Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac in-patients | |
Hodoba et al. | Biperiden for treatment of somnambulism in adolescents and adults with or without epilepsy: Clinical observations | |
Mitler | Evaluation of temazepam as a hypnotic | |
KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
AU736514B2 (en) | Non-allosteric gabaa agonists for treating sleep disorders | |
Feldmeier et al. | Comparative clinical studies with midazolam, oxazepam and placebo. | |
CA2550610A1 (en) | Use of gaboxadol for treating insomnia | |
US5362731A (en) | Use of piribedil derivatives and analogs for the treatment of hyperactive or unstable bladders | |
AU2019250266A2 (en) | Melatonin agonist treatment | |
Cohen et al. | Spontaneous EEG Changes During Tobacco Abstinence are Reversed by Caffeine | |
HU190714B (en) | Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040527 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051219 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091222 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101222 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |